Baak, L.C.

( L.C. Baak)

patient load decrease hepatitis response hcv mono-infected patients ﬁ rst phase hepatitis c decrease hcv /hiv patients therapy mono-infected slope study virus treatment phase baseline ﬁ rst-phase ribavirin kinetic hepatitis c virus rst-phase genotype interferon analysis responder hcv mono-infected difference hcv-rna group hepatitis c mono-infected rvr patients ﬁciency week 12 peginterferon-alfa plasma virological response non-rvr non-rvr patients immunode ﬁciency virus data analysis second-phase slope hiv /hcv patients genotype 1 assay factor hepatology signi model zeuzem day 2 50 iu /ml effect infection interest ﬁ rst-phase kinetics publishing blackwell ﬁ rst-phase slope ﬁ rst-phase response second-phase ef ﬁciency factor hepatol sample svr rate layden tj liver netherland virological ribavirin therapy ﬁcant roche decline manuscript arend combination monoinfected utrecht disease signi ﬁcant

1 Most Recent Publications

Plasma HCV-RNA decline in the first 48 h identifies hepatitis C virus mono-infected but not HCVHIV-coinfected patients with an undetectable HCV viral load at week 4 of peginterferon-alfa-2aribavirin therapy (Article)
Arends, J.E. Stuart, J.C. Baak, L.C. Ende, M.E. van der Erpecum, K.J. van Simons, C.P.M. Boland , G.J. Baarle, D. van Hoepelman, I.M.

2009-12-01

Message*:
Your Email Adress*:
	*: Required fields, please provide an email address so that the RePub team can contact you if needed.